Gabapentin use and a claim for memory loss in Kentucky

Kentucky is a focal jurisdiction for gabapentin litigation, combining some of the highest per-capita prescribing rates in the nation with early regulatory action that acknowledged the drug's dangers. Kentucky classified gabapentin as a Schedule V controlled substance in 2017 — one of the first states to do so — after the state's KASPER prescription monitoring program revealed alarming co-prescribing patterns with opioids. Eastern Kentucky's Appalachian communities bore the brunt of the opioid crisis and subsequently received massive gabapentin prescribing as physicians sought alternatives, creating a population with extended high-dose exposure and minimal cognitive monitoring. The state's aggressive plaintiff bar and experienced mass tort judges, particularly in Jefferson County (Louisville), make Kentucky one of the strongest jurisdictions for gabapentin cognitive decline claims.

For the overall process and updates, read the Gabapentin use and a claim for memory loss overview. This page covers the local information available for Kentucky.